-- Announcement on Pledge of Partial Shares of Controlling Shareholder
Securities code: 603880 Securities abbreviation: Nanwei Shares Announcement number: 2025-023
About Jiangsu Nanfang Health Care Pharmaceutical Co., Ltd.
Announcement on the pledge of part of the controlling shareholder’s shares
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Important content reminder:
As of the disclosure date of this announcement, Mr. Li Ping, the controlling shareholder of Jiangsu Southern Weisai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), holds 118,841,048 shares of the company, accounting for 41.12% of the company's total share capital. The company's controlling shareholder Mr. Li Ping and persons acting in concert Mr. Li Yongping and Mr. Li Yongzhong hold a total of 136,560,415 shares of the company, accounting for 47.25% of the company's total share capital. After this partial share pledge, Mr. Li Ping pledged a total of 87,400,000 company shares, accounting for 73.54% of the total number of company shares he holds and 10% of the company's total share capital. 30.24%. Mr. Li Ping and his persons acting in concert, Mr. Li Yongping and Mr. Li Yongzhong, have pledged a total of 97,039,338 shares of the company, accounting for 71.06% of the total number of shares held by them and 33.57% of the company's total share capital.
The company received a notice from the company's controlling shareholder Mr. Li Ping on September 23, 2025, and learned that part of the company's shares held by him were pledged. The specific matters are as follows:
1. Pledge of shares of listed companies
- Basic situation of this share pledge
Whether it is a shareholder of pledged financing, the shares pledged this time account for its total holdings of the company's total
Limited to controlling shares. Supplement. Pledge starting date. Pledge expiry date. Pledgee. Capital name. Number of shares (shares). Share ratio. Share capital ratio.
Dong sells shares, pledges, and uses the shares to be processed Bank of Nanjing shares
Supplementary flow Li Ping Yes 3,000,000 No No 2025.9.22 Release of pledge and registration Co., Ltd. 2.52% 1.04%
working capital
Date of Record Changzhou Branch
Total - 3,000,000 - - - - - 2.52% 1.04% -
This pledge of shares does not involve being used as a guarantee or other guarantee for major asset restructuring, performance compensation and other matters.
Accumulative pledged shares by shareholders
As of the announcement date, the cumulative pledged shares of the above shareholders and their persons acting in concert are as follows:
Situation of pledged shares Situation of unpledged shares Pledged Not pledged Not pledged
Before this pledge, after this pledge, accumulated shares of the company were accumulated
Name of shareholder Number of shares held Shareholding ratio Number of shares Pledged shares Number of shares Number of shares
Cumulative number of pledges Total number of pledges Shares held Total share capital
Name (share) Example Restricted shares Frozen shares Restricted shares Frozen shares (shares) (shares) Ratio Ratio
Number of shares Number of shares Number of shares Number of shares
(Share) (Share) (Share) Li Ping 118,841,048 41.12% 84,400,000 87,400,000 73.54% 30.24% 0 87,400,000 0 0Li Yongping 9,639,338 3.33% 9,639,338 9,639,338 100% 3.33% 0 9,639,338 0 0Li Yongzhong 8,080,029 2.80% 0 0 0 0 0 0 0 0Total 136,560,415 47.25% 94,039,338 97,039,338 71.06% 33.57% 0 97,039,338 0 0
2. Pledge of shares of controlling shareholders of listed companies
- The number of pledged shares due by the controlling shareholder and its persons acting in concert in the next six months is 59.4 million shares, accounting for 20.55% of the company's total share capital and 43.50% of the company's shares held by the controlling shareholder and persons acting in concert. The balance of the above equity pledge financing is 115 million yuan. The number of pledged shares due by the controlling shareholder and its persons acting in concert in the next year (excluding those due within half a year) is 0 shares, accounting for 0% of the company’s total share capital, and 0% of the company’s shares held by the controlling shareholder and persons acting in concert.
The pledge risk of the controlling shareholder Mr. Li Ping and his concerted parties is within controllable limits. If the risk of liquidation arises in the future, the pledger will actively respond with self-raised funds such as stock dividends, share reductions, investment income and other income, and take partial early repayment and other measures to actively respond.
Up to now, the company’s controlling shareholder and its related parties have not infringed upon the interests of the listed company through occupation of non-operating funds, illegal guarantees, related transactions, etc.
The impact of controlling shareholder’s pledge on listed companies
(1) This pledge by the controlling shareholder will not have a significant impact on the company’s main business, financing credit and financing costs, and continued operating capabilities;
(2) This pledge by the controlling shareholder will not affect the shareholder’s appointment of director seats to the listed company, nor will it affect the relationship between the shareholder and the listed company in terms of property rights, business, assets, personnel, etc., nor will it affect the stability of the company’s control rights, equity structure, and daily management;
(3) The controlling shareholder has no performance compensation obligations that must be fulfilled.
The company will continue to pay attention to the above-mentioned share pledge situation and pledge risk situation, and make relevant information disclosures in a timely manner as required. Investors are kindly requested to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jiangsu Southern Health Care Pharmaceutical Co., Ltd.
September 24, 2025